ATHENA THERAPEUTICS

Athena Therapeutics developed cutting-edge approaches to probe for, identify, and characterize altered states of NAD metabolism and flux. The Company has recruited a team of researchers with critical expertise in NAD metabolism including Dr. Emmanuel Burgos, formerly of the Albert Einstein College of Medicine, to lead the internal discovery biology capabilities and establish a suite of NAD pathway targets for development. To complement internal expertise, Athena has assembled a Scientific Advisory Board of world experts, which includes Professor Vern Schramm of the Albert Einstein College of Medicine, a world-renown enzymologist specializing in NAMPT and drug design, and Dr. Leonard Post, a seasoned oncology drug developer and discoverer of the PARP inhibitor talazoparib.